DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights.

AIM To define the DNA methylation landscape of neuroblastoma and its clinicopathological impact. MATERIALS & METHODS Microarray DNA methylation data were analyzed and associated with functional/regulatory genome annotation data, transcriptional profiles and clinicobiological parameters. RESULTS DNA methylation changes in neuroblastoma affect not only promoters but also intragenic and intergenic regions at cytosine-phosphate-guanine (CpG) and non-CpG sites, and target functional chromatin domains of development and cancer-related genes such as CCND1. Tumors with diverse clinical risk showed differences affecting CpG and, remarkably, non-CpG sites. Non-CpG methylation observed essentially in clinically favorable cases was associated with the differentiation status of neuroblastoma and expression of key genes such as ALK. CONCLUSION This epigenetic fingerprint of neuroblastoma provides new insights into the pathogenesis and clinical behavior of this pediatric tumor.

[1]  A. Conesa,et al.  Two independent epigenetic biomarkers predict survival in neuroblastoma , 2015, Clinical Epigenetics.

[2]  Michael Q. Zhang,et al.  Integrative analysis of 111 reference human epigenomes , 2015, Nature.

[3]  Hiromu Suzuki,et al.  Biological significance of the CpG island methylator phenotype. , 2014, Biochemical and biophysical research communications.

[4]  David J. Duffy,et al.  p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. , 2014, Human molecular genetics.

[5]  A. Nakagawara,et al.  RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients. , 2014, Cancer letters.

[6]  Guoping Fan,et al.  Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain , 2013, Nature Neuroscience.

[7]  J. Martín-Subero,et al.  Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. , 2013, Biochimica et biophysica acta.

[8]  E. Koonin,et al.  Differences in DNA methylation between human neuronal and glial cells are concentrated in enhancers and non-CpG sites , 2013, Nucleic acids research.

[9]  G. Hon,et al.  Adult tissue methylomes harbor epigenetic memory at embryonic enhancers , 2013, Nature Genetics.

[10]  Matthew D. Schultz,et al.  Global Epigenomic Reconfiguration During Mammalian Brain Development , 2013, Science.

[11]  D. Aran,et al.  DNA Methylation of Transcriptional Enhancers and Cancer Predisposition , 2013, Cell.

[12]  F. Westermann,et al.  Stronger prognostic power of the CpG island methylator phenotype than methylation of individual genes in neuroblastomas. , 2013, Japanese journal of clinical oncology.

[13]  Wei Lu,et al.  Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. , 2013, American journal of human genetics.

[14]  M. Truong,et al.  Analysis of promoter non-CG methylation in prostate cancer. , 2013, Epigenomics.

[15]  Zachary D. Smith,et al.  DNA methylation: roles in mammalian development , 2013, Nature Reviews Genetics.

[16]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[17]  R. Siebert,et al.  Base-pair resolution DNA methylome of the EBV-positive Endemic Burkitt lymphoma cell line DAUDI determined by SOLiD bisulfite-sequencing , 2013, Leukemia.

[18]  Giovanni Parmigiani,et al.  Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.

[19]  M. Esteller,et al.  DNA Hypomethylation Affects Cancer-Related Biological Functions and Genes Relevant in Neuroblastoma Pathogenesis , 2012, PloS one.

[20]  Alfonso Valencia,et al.  Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia , 2012, Nature Genetics.

[21]  W. K. Kok,et al.  SUMO Modification of Stra13 Is Required for Repression of Cyclin D1 Expression and Cellular Growth Arrest , 2012, PloS one.

[22]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[23]  Y. Mossé,et al.  Targeting ALK in neuroblastoma—preclinical and clinical advancements , 2012, Nature Reviews Clinical Oncology.

[24]  Julie V. Harness,et al.  Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. , 2012, Cell stem cell.

[25]  N. Olgun,et al.  Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors. , 2012, Cancer letters.

[26]  Jinghui Zhang,et al.  Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.

[27]  C. Brigati,et al.  A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype , 2012, Laboratory Investigation.

[28]  D. Zwijnenburg,et al.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.

[29]  J. Mora,et al.  A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma , 2012, Clinical Cancer Research.

[30]  W. London,et al.  Mechanisms of CHD5 Inactivation in Neuroblastomas , 2012, Clinical Cancer Research.

[31]  P. Laird,et al.  Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina–associated domains , 2011, Nature Genetics.

[32]  K. Gunderson,et al.  High density DNA methylation array with single CpG site resolution. , 2011, Genomics.

[33]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[34]  R. Stewart,et al.  Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells , 2011, Nature.

[35]  J. Mora,et al.  Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma , 2010, Molecular Cancer.

[36]  Steven S. Smith,et al.  Human non-CG methylation , 2010, Epigenetics.

[37]  D. Geerts,et al.  Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells , 2010, Oncogene.

[38]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[39]  G. Tonini,et al.  Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. , 2009, Cancer research.

[40]  Madeleine P. Ball,et al.  Targeted and genome-scale methylomics reveals gene body signatures in human cell lines , 2009, Nature Biotechnology.

[41]  F. Speleman,et al.  Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. , 2009, Cancer letters.

[42]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  H. Carén,et al.  High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. , 2008, The Biochemical journal.

[44]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[45]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[46]  Leslie Cope,et al.  Convergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis , 2008, PLoS medicine.

[47]  M. Esteller.  Epigenetics in cancer. , 2008, The New England journal of medicine.

[48]  P. White,et al.  Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas , 2008, Oncogene.

[49]  Wei Chen,et al.  Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer , 2007, PLoS genetics.

[50]  B. Brumback,et al.  Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome , 2007, Clinical Cancer Research.

[51]  F. Westermann,et al.  Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. , 2007, Cancer letters.

[52]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[53]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[54]  A. Bird,et al.  Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  F. Behm,et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.

[56]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.